MedPath

Prevalence and Characteristics of Intimate Partner Violence Against Individuals Seeking Hematological Consultations

Terminated
Conditions
Pulmonary Embolism and Thrombosis
Intimate Partner Violence
Deep Vein Thrombosis (DVT)/Thrombophlebitis
Registration Number
NCT06415968
Lead Sponsor
Centre Hospitalier Universitaire de Nīmes
Brief Summary

Intimate violence against individuals, which is particularly marked among women, is one of the most widespread human rights violations in the world.

The Women Abuse Screening Tool (WAST) self-questionnaire is a screening tool validated in French.

Our preliminary data describing the association between intimate violence against women and the first attack of unexplained venous thromboembolic disease, show a significant frequency of positive responses to the WAST among women attending a biological hematology consultation at the CHU de Nîmes, for reasons of hemostasis disorders (8% out of the first 200 cases).

The study authors wish to establish the prevalence of this situation among patients presenting to the CHU de Nîmes for hematological exploration and management. They hypothesize that the prevalence of violence against individuals seen in Hematology consultations is higher among individuals with hemostasis pathologies (hemorrhagic and thrombotic pathologies) than those with cellular pathologies, and higher among women than men.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
138
Inclusion Criteria
  • Currently in a relationship or has been in one in the last 12 months, regardless of the length of the relationship

  • Willing to complete the anonymous WAST self-questionnaire

  • able to read and understand French

  • Outpatient consultant at Nîmes University Hospital in one of the following departments:

    • Biological hematology consultation
    • Clinical hematology consultation
    • Vascular medicine consultation
Exclusion Criteria
  • Individuals under court protection, guardianship or curatorship
  • Individuals unable to read and understand French
  • Individuals who have already completed the WAST questionnaire during the study period
  • Individuals unable to get away from their partner during the consultation to complete the questionnaire in isolation

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Prevalence of patients experiencing Intimate Partner Violence according to consulting departmentDay 0

Percentage of patients with a Women Abuse Screening Tool (WAST) score ≥ 5 consulting in the hemostasis pathology versus cellular hematological pathology department. The WAST is an 8-item questionnaire with a score ranging from 0 to 16 (worst violence), with a cut-off of 5 for presence of violence

Secondary Outcome Measures
NameTimeMethod
Prevalence of Intimate Partner Violence according to patient disease status and genderDay 0

WAST questionnaire total score in women versus men, for hemostasis disease versus cellular hematological disease versus hemorrhagic symptomatology versus thrombotic symptomatology

Prevalence of Intimate Partner Violence in men versus women according to consulting departmentDay 0

WAST score ≥ 5 consulting in the hemostasis pathology versus cellular hematological pathology department in women versus men

WAST questionnaire score according to patient disease status and genderDay 0

Score for individual items of WAST questionnaire in women versus men, for hemostasis disease versus cellular hematological disease versus hemorrhagic symptomatology versus thrombotic symptomatology

Association between the major risk factors for Intimate Partner Violence and WAST score.Day 0

WAST questionnaire total score according to: Number of years together, Violence at home growing up, Marital status (divorced or separated), Children living at home, Working status, Finances (personal income, financial difficulties), Living status (together vs separate, size of dwelling, neighbors nearby), Health status of living partner, Health status of patient

Trial Locations

Locations (1)

CHU de Nimes

🇫🇷

Nîmes, France

© Copyright 2025. All Rights Reserved by MedPath